U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C26H28ClNO.C6H8O7
Molecular Weight 598.083
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of TOREMIFENE CITRATE

SMILES

OC(=O)CC(O)(CC(O)=O)C(O)=O.CN(C)CCOC1=CC=C(C=C1)C(=C(\CCCl)C2=CC=CC=C2)\C3=CC=CC=C3

InChI

InChIKey=IWEQQRMGNVVKQW-OQKDUQJOSA-N
InChI=1S/C26H28ClNO.C6H8O7/c1-28(2)19-20-29-24-15-13-23(14-16-24)26(22-11-7-4-8-12-22)25(17-18-27)21-9-5-3-6-10-21;7-3(8)1-6(13,5(11)12)2-4(9)10/h3-16H,17-20H2,1-2H3;13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)/b26-25-;

HIDE SMILES / InChI
Molecular Formula C6H8O7
Molecular Weight 192.1235
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula C26H28ClNO
Molecular Weight 405.96
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 1
Optical Activity NONE

Description
Curator's Comment: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020497s006lbl.pdf

Toremifene is an antineoplastic hormonal agent primarily used in the treatment of advanced breast cancer. Toremifene is a nonsteroidal agent that has demonstrated potent antiestrogenic properties in animal test systems. The antiestrogenic effects may be related to its ability to compete with estrogen for binding sites in target tissues such as breast. Toremifene inhibits the induction of rat mammary carcinoma induced by dimethylbenzanthracene (DMBA) and causes the regression of already established DMBA-induced tumors. In this rat model, Toremifene appears to exert its antitumor effects by binding the estrogen receptors. In cytosols derived from human breast adenocarcinomas, Toremifene competes with estradiol for estrogen receptor protein. Toremifene is a nonsteroidal triphenylethylene derivative. Toremifene binds to estrogen receptors and may exert estrogenic, antiestrogenic, or both activities, depending upon the duration of treatment, animal species, gender, target organ, or endpoint selected. The antitumor effect of toremifene in breast cancer is believed to be mainly due to its antiestrogenic effects, in other words, its ability to compete with estrogen for binding sites in the cancer, blocking the growth-stimulating effects of estrogen in the tumor. Toremifene may also inhibit tumor growth through other mechanisms, such as induction of apoptosis, regulation of oncogene expression, and growth factors. Toremifene is used for the treatment of metastatic breast cancer in postmenopausal women with estrogen receptor-positive or receptor-unknown tumors. Toremifene is currently under investigation as a preventative agent for prostate cancer in men with high-grade prostatic intraepithelial neoplasia and no evidence of prostate cancer. Toremifene is marketed in the United States under the brand name Fareston.

Originator

Approval Year

1997
172
Targets

Targets

Primary TargetPharmacologyConditionPotency
Modulator
828
Thyroid carcinoma cell lines
2
Target ID: Thyroid carcinoma cell lines
Inhibitor
8297
Inhibitor
8297
 1.2 µM [IC50]
Inhibitor
8297
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8429
FARESTON

Approved Use

FARESTON® is an estrogen agonist/antagonist indicated for the treatment of metastatic breast cancer in postmenopausal women with estrogen-receptor positive or unknown tumors.

Launch Date

8.647776E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
414 ng/mL
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/7781262
120 mg single, oral
dose: 120 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TOREMIFENE blood
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
722 ng/mL
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/9871429
120 mg single, oral
dose: 120 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TOREMIFENE blood
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
28.4 μg × h/mL
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/7781262
120 mg single, oral
dose: 120 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TOREMIFENE blood
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
34.1 μg × h/mL
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/9871429
120 mg single, oral
dose: 120 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TOREMIFENE blood
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
6.2 day
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/7781262
120 mg single, oral
dose: 120 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TOREMIFENE blood
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
99 h
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/9871429
120 mg single, oral
dose: 120 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TOREMIFENE blood
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
400 mg/m2 1 times / day steady, oral
MTD
Dose: 400 mg/m2, 1 times / day
Route: oral
Route: steady
Dose: 400 mg/m2, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1385761/
Page: 175
unhealthy, 38 - 79 years
n = 5
Health Status: unhealthy
Condition: metastatic breast cancer
Age Group: 38 - 79 years
Sex: F
Population Size: 5
Sources:
https://pubmed.ncbi.nlm.nih.gov/1385761/
Page: 175
DLT: Nausea and vomiting, Dizziness...
Other AEs: Sweating, Peripheral edema...
Dose limiting toxicities:
Nausea and vomiting (grade 1-4, 5 patients)
Dizziness (grade 1-4, 4 patients)
Other AEs:
Sweating (grade 1-4, 3 patients)
Peripheral edema (grade 1-4, 3 patients)
Vaginal discharge (grade 1-4, 0%)
Hot flushes (grade 1-4, 2 patients)
Sources:
https://pubmed.ncbi.nlm.nih.gov/1385761/
Page: 175
200 mg/m2 1 times / day steady, oral
Recommended
Dose: 200 mg/m2, 1 times / day
Route: oral
Route: steady
Dose: 200 mg/m2, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1385761/
Page: 175
unhealthy, 38 - 79 years
n = 8
Health Status: unhealthy
Condition: metastatic breast cancer
Age Group: 38 - 79 years
Sex: F
Population Size: 8
Sources:
https://pubmed.ncbi.nlm.nih.gov/1385761/
Page: 175
Other AEs: Nausea and vomiting, Dizziness...
Other AEs:
Nausea and vomiting (grade 1-4, 7 patients)
Dizziness (grade 1-4, 2 patients)
Sweating (grade 1-4, 2 patients)
Peripheral edema (grade 1-4, 2 patients)
Vaginal discharge (grade 1-4, 2 patients)
Hot flushes (grade 1-4, 1 patient)
Sources:
https://pubmed.ncbi.nlm.nih.gov/1385761/
Page: 175
300 mg/m2 1 times / day steady, oral
Recommended
Dose: 300 mg/m2, 1 times / day
Route: oral
Route: steady
Dose: 300 mg/m2, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1385761/
Page: 175
unhealthy, 38 - 79 years
n = 6
Health Status: unhealthy
Condition: metastatic breast cancer
Age Group: 38 - 79 years
Sex: F
Population Size: 6
Sources:
https://pubmed.ncbi.nlm.nih.gov/1385761/
Page: 175
Other AEs: Nausea and vomiting, Dizziness...
Other AEs:
Nausea and vomiting (grade 1-4, 6 patients)
Dizziness (grade 1-4, 4 patients)
Sweating (grade 1-4, 3 patients)
Peripheral edema (grade 1-4, 4 patients)
Vaginal discharge (grade 1-4, 3 patients)
Hot flushes (grade 1-4, 4 patients)
Sources:
https://pubmed.ncbi.nlm.nih.gov/1385761/
Page: 175
AEs

AEs

AESignificanceDosePopulation
Vaginal discharge grade 1-4, 0%
400 mg/m2 1 times / day steady, oral
MTD
Dose: 400 mg/m2, 1 times / day
Route: oral
Route: steady
Dose: 400 mg/m2, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1385761/
Page: 175
unhealthy, 38 - 79 years
n = 5
Health Status: unhealthy
Condition: metastatic breast cancer
Age Group: 38 - 79 years
Sex: F
Population Size: 5
Sources:
https://pubmed.ncbi.nlm.nih.gov/1385761/
Page: 175
Hot flushes grade 1-4, 2 patients
400 mg/m2 1 times / day steady, oral
MTD
Dose: 400 mg/m2, 1 times / day
Route: oral
Route: steady
Dose: 400 mg/m2, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1385761/
Page: 175
unhealthy, 38 - 79 years
n = 5
Health Status: unhealthy
Condition: metastatic breast cancer
Age Group: 38 - 79 years
Sex: F
Population Size: 5
Sources:
https://pubmed.ncbi.nlm.nih.gov/1385761/
Page: 175
Peripheral edema grade 1-4, 3 patients
400 mg/m2 1 times / day steady, oral
MTD
Dose: 400 mg/m2, 1 times / day
Route: oral
Route: steady
Dose: 400 mg/m2, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1385761/
Page: 175
unhealthy, 38 - 79 years
n = 5
Health Status: unhealthy
Condition: metastatic breast cancer
Age Group: 38 - 79 years
Sex: F
Population Size: 5
Sources:
https://pubmed.ncbi.nlm.nih.gov/1385761/
Page: 175
Sweating grade 1-4, 3 patients
400 mg/m2 1 times / day steady, oral
MTD
Dose: 400 mg/m2, 1 times / day
Route: oral
Route: steady
Dose: 400 mg/m2, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1385761/
Page: 175
unhealthy, 38 - 79 years
n = 5
Health Status: unhealthy
Condition: metastatic breast cancer
Age Group: 38 - 79 years
Sex: F
Population Size: 5
Sources:
https://pubmed.ncbi.nlm.nih.gov/1385761/
Page: 175
Dizziness grade 1-4, 4 patients
DLT
400 mg/m2 1 times / day steady, oral
MTD
Dose: 400 mg/m2, 1 times / day
Route: oral
Route: steady
Dose: 400 mg/m2, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1385761/
Page: 175
unhealthy, 38 - 79 years
n = 5
Health Status: unhealthy
Condition: metastatic breast cancer
Age Group: 38 - 79 years
Sex: F
Population Size: 5
Sources:
https://pubmed.ncbi.nlm.nih.gov/1385761/
Page: 175
Nausea and vomiting grade 1-4, 5 patients
DLT
400 mg/m2 1 times / day steady, oral
MTD
Dose: 400 mg/m2, 1 times / day
Route: oral
Route: steady
Dose: 400 mg/m2, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1385761/
Page: 175
unhealthy, 38 - 79 years
n = 5
Health Status: unhealthy
Condition: metastatic breast cancer
Age Group: 38 - 79 years
Sex: F
Population Size: 5
Sources:
https://pubmed.ncbi.nlm.nih.gov/1385761/
Page: 175
Hot flushes grade 1-4, 1 patient
200 mg/m2 1 times / day steady, oral
Recommended
Dose: 200 mg/m2, 1 times / day
Route: oral
Route: steady
Dose: 200 mg/m2, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1385761/
Page: 175
unhealthy, 38 - 79 years
n = 8
Health Status: unhealthy
Condition: metastatic breast cancer
Age Group: 38 - 79 years
Sex: F
Population Size: 8
Sources:
https://pubmed.ncbi.nlm.nih.gov/1385761/
Page: 175
Dizziness grade 1-4, 2 patients
200 mg/m2 1 times / day steady, oral
Recommended
Dose: 200 mg/m2, 1 times / day
Route: oral
Route: steady
Dose: 200 mg/m2, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1385761/
Page: 175
unhealthy, 38 - 79 years
n = 8
Health Status: unhealthy
Condition: metastatic breast cancer
Age Group: 38 - 79 years
Sex: F
Population Size: 8
Sources:
https://pubmed.ncbi.nlm.nih.gov/1385761/
Page: 175
Peripheral edema grade 1-4, 2 patients
200 mg/m2 1 times / day steady, oral
Recommended
Dose: 200 mg/m2, 1 times / day
Route: oral
Route: steady
Dose: 200 mg/m2, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1385761/
Page: 175
unhealthy, 38 - 79 years
n = 8
Health Status: unhealthy
Condition: metastatic breast cancer
Age Group: 38 - 79 years
Sex: F
Population Size: 8
Sources:
https://pubmed.ncbi.nlm.nih.gov/1385761/
Page: 175
Sweating grade 1-4, 2 patients
200 mg/m2 1 times / day steady, oral
Recommended
Dose: 200 mg/m2, 1 times / day
Route: oral
Route: steady
Dose: 200 mg/m2, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1385761/
Page: 175
unhealthy, 38 - 79 years
n = 8
Health Status: unhealthy
Condition: metastatic breast cancer
Age Group: 38 - 79 years
Sex: F
Population Size: 8
Sources:
https://pubmed.ncbi.nlm.nih.gov/1385761/
Page: 175
Vaginal discharge grade 1-4, 2 patients
200 mg/m2 1 times / day steady, oral
Recommended
Dose: 200 mg/m2, 1 times / day
Route: oral
Route: steady
Dose: 200 mg/m2, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1385761/
Page: 175
unhealthy, 38 - 79 years
n = 8
Health Status: unhealthy
Condition: metastatic breast cancer
Age Group: 38 - 79 years
Sex: F
Population Size: 8
Sources:
https://pubmed.ncbi.nlm.nih.gov/1385761/
Page: 175
Nausea and vomiting grade 1-4, 7 patients
200 mg/m2 1 times / day steady, oral
Recommended
Dose: 200 mg/m2, 1 times / day
Route: oral
Route: steady
Dose: 200 mg/m2, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1385761/
Page: 175
unhealthy, 38 - 79 years
n = 8
Health Status: unhealthy
Condition: metastatic breast cancer
Age Group: 38 - 79 years
Sex: F
Population Size: 8
Sources:
https://pubmed.ncbi.nlm.nih.gov/1385761/
Page: 175
Sweating grade 1-4, 3 patients
300 mg/m2 1 times / day steady, oral
Recommended
Dose: 300 mg/m2, 1 times / day
Route: oral
Route: steady
Dose: 300 mg/m2, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1385761/
Page: 175
unhealthy, 38 - 79 years
n = 6
Health Status: unhealthy
Condition: metastatic breast cancer
Age Group: 38 - 79 years
Sex: F
Population Size: 6
Sources:
https://pubmed.ncbi.nlm.nih.gov/1385761/
Page: 175
Vaginal discharge grade 1-4, 3 patients
300 mg/m2 1 times / day steady, oral
Recommended
Dose: 300 mg/m2, 1 times / day
Route: oral
Route: steady
Dose: 300 mg/m2, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1385761/
Page: 175
unhealthy, 38 - 79 years
n = 6
Health Status: unhealthy
Condition: metastatic breast cancer
Age Group: 38 - 79 years
Sex: F
Population Size: 6
Sources:
https://pubmed.ncbi.nlm.nih.gov/1385761/
Page: 175
Dizziness grade 1-4, 4 patients
300 mg/m2 1 times / day steady, oral
Recommended
Dose: 300 mg/m2, 1 times / day
Route: oral
Route: steady
Dose: 300 mg/m2, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1385761/
Page: 175
unhealthy, 38 - 79 years
n = 6
Health Status: unhealthy
Condition: metastatic breast cancer
Age Group: 38 - 79 years
Sex: F
Population Size: 6
Sources:
https://pubmed.ncbi.nlm.nih.gov/1385761/
Page: 175
Hot flushes grade 1-4, 4 patients
300 mg/m2 1 times / day steady, oral
Recommended
Dose: 300 mg/m2, 1 times / day
Route: oral
Route: steady
Dose: 300 mg/m2, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1385761/
Page: 175
unhealthy, 38 - 79 years
n = 6
Health Status: unhealthy
Condition: metastatic breast cancer
Age Group: 38 - 79 years
Sex: F
Population Size: 6
Sources:
https://pubmed.ncbi.nlm.nih.gov/1385761/
Page: 175
Peripheral edema grade 1-4, 4 patients
300 mg/m2 1 times / day steady, oral
Recommended
Dose: 300 mg/m2, 1 times / day
Route: oral
Route: steady
Dose: 300 mg/m2, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1385761/
Page: 175
unhealthy, 38 - 79 years
n = 6
Health Status: unhealthy
Condition: metastatic breast cancer
Age Group: 38 - 79 years
Sex: F
Population Size: 6
Sources:
https://pubmed.ncbi.nlm.nih.gov/1385761/
Page: 175
Nausea and vomiting grade 1-4, 6 patients
300 mg/m2 1 times / day steady, oral
Recommended
Dose: 300 mg/m2, 1 times / day
Route: oral
Route: steady
Dose: 300 mg/m2, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1385761/
Page: 175
unhealthy, 38 - 79 years
n = 6
Health Status: unhealthy
Condition: metastatic breast cancer
Age Group: 38 - 79 years
Sex: F
Population Size: 6
Sources:
https://pubmed.ncbi.nlm.nih.gov/1385761/
Page: 175
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:9635
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:9635
ChemicalBook
CB0287854
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB0287854
ZINC
ZINC000012404516
http://zinc15.docking.org/substances/ZINC000012404516
PubMed

PubMed

TitleDatePubMed
Toremifene enhances cell cycle block and growth inhibition by vinblastine in multidrug resistant human breast cancer cells.
1993
Major difference in the hepatocarcinogenicity and DNA adduct forming ability between toremifene and tamoxifen in female Crl:CD(BR) rats.
1993 Oct 1
Peroxidase activation of tamoxifen and toremifene resulting in DNA damage and covalently bound protein adducts.
1995 Mar
Comparison of the effects of tamoxifen and toremifene on liver and kidney tumor promotion in female rats.
1995 Nov
A two-year dietary carcinogenicity study of the antiestrogen toremifene in Sprague-Dawley rats.
1996 Nov
Structure-activity relationships for triphenylethylene antiestrogens on hepatic phase-I and phase-II enzyme expression.
1998 Aug 1
Toremifene-induced fatty liver and NASH in breast cancer patients with breast-conservation treatment.
2000 Dec
Comparison of the effects of tamoxifen and toremifene on rat hepatocarcinogenesis.
2000 Jul
Prediction of genotoxicity of chemical compounds by statistical learning methods.
2005 Jun
Role of 5a-reductase inhibitors and selective estrogen receptor modulators as potential chemopreventive agents for prostate cancer.
2005 Mar
Drug resistance in chemotherapy for breast cancer.
2005 Nov
Estrogen receptors as therapeutic targets in breast cancer.
2006
Histopathology and histomorphometry of the urogenital tract in 15-month old male and female rats treated neonatally with SERMs and estrogens.
2006 Aug
In silico prediction of pregnane X receptor activators by machine learning approaches.
2007 Jan
Chemoprevention of prostate cancer: agents and study designs.
2007 Sep
Human sex hormone-binding globulin binding affinities of 125 structurally diverse chemicals and comparison with their binding to androgen receptor, estrogen receptor, and α-fetoprotein.
2015 Feb
Utilization of human nuclear receptors as an early counter screen for off-target activity: a case study with a compendium of 615 known drugs.
2015 Jun
Patents

Patents

JP2001139474A
10
JP2001335484A
8
JP2002517433A
15
JP2002521322A
20
JP2002522389A
24
JP2002535628A
9
JP2002535635A
5
JP2002537317A
97
JP2003055207A
2
JP2003529540A
49
JP2006502184A
41
JP2006507253A
19
JP2006519264A
58
JP2006526415A
5
JP2007504131A
12
JP2007518721A
16
JP2008156239A
2
JP2008163048A
2
JP2008533018A
15
JP2008533019A
34
JP2009029823A
2
JP2009509910A
2
JP2009513567A
65
JP2009537636A
13
JP2010526091A
24
JP2011506455A
51
JP2011525105A
6
JP2011525180A
180
JP2011528275A
455
JP4658037B2
37
JP4740878B2
4
JP4799864B2
33
JP4832303B2
14
JPH03163015A
2
JPH10147522A
6

Sample Use Guides

In Vivo Use Guide
60 mg once daily, orally
Route of Administration: Oral
In Vitro Use Guide
Treatment of the human breast cancer cell line MCF-7 with 7.5 uM toremifene for 3 days caused approximately 60% of the cells to exhibit morphologic characteristics typical of cells undergoing apoptosis.
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:09:55 UTC 2023
Edited
by admin
on Fri Dec 15 15:09:55 UTC 2023
Record UNII
2498Y783QT
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
TOREMIFENE CITRATE
JAN   MART.   MI   ORANGE BOOK   USAN   VANDF   WHO-DD  
USAN  
Official Name English
Toremifene citrate [WHO-DD]
Common Name English
2-[P-[(Z)-4-Chloro-1,2-diphenyl-1-butenyl]phenoxy]-N,N-dimethylethylamine citrate (1:1)
Common Name English
TOREMIFENE CITRATE [ORANGE BOOK]
Common Name English
FC-1157A
Code English
TOREMIFENE CITRATE [MART.]
Common Name English
ETHANAMINE, 2-(4-(4-CHLORO-1,2-DIPHENYL-1-BUTENYL)PHENOXY)-N,N-DIMETHYL-, (Z)-, 2-HYDROXY-1,2,3-PROPANETRICARBOXYLATE (1:1)
Common Name English
FARESTON
Brand Name English
TOREMIFENE CITRATE [VANDF]
Common Name English
TOREMIFENE CITRATE [MI]
Common Name English
TOREMIFENE CITRATE [USAN]
Common Name English
TOREMIFENE CITRATE [JAN]
Common Name English
NSC-613680
Code English
Classification Tree Code System Code
NCI_THESAURUS C1821
Created by admin on Fri Dec 15 15:09:55 UTC 2023 , Edited by admin on Fri Dec 15 15:09:55 UTC 2023
Code System Code Type Description
DAILYMED
2498Y783QT
Created by admin on Fri Dec 15 15:09:55 UTC 2023 , Edited by admin on Fri Dec 15 15:09:55 UTC 2023
PRIMARY
NCI_THESAURUS
C1756
Created by admin on Fri Dec 15 15:09:55 UTC 2023 , Edited by admin on Fri Dec 15 15:09:55 UTC 2023
PRIMARY
USAN
Z-51
Created by admin on Fri Dec 15 15:09:55 UTC 2023 , Edited by admin on Fri Dec 15 15:09:55 UTC 2023
PRIMARY
NSC
613680
Created by admin on Fri Dec 15 15:09:55 UTC 2023 , Edited by admin on Fri Dec 15 15:09:55 UTC 2023
PRIMARY
FDA UNII
2498Y783QT
Created by admin on Fri Dec 15 15:09:55 UTC 2023 , Edited by admin on Fri Dec 15 15:09:55 UTC 2023
PRIMARY
RXCUI
49953
Created by admin on Fri Dec 15 15:09:55 UTC 2023 , Edited by admin on Fri Dec 15 15:09:55 UTC 2023
PRIMARY RxNorm
EPA CompTox
DTXSID2021367
Created by admin on Fri Dec 15 15:09:55 UTC 2023 , Edited by admin on Fri Dec 15 15:09:55 UTC 2023
PRIMARY
DRUG BANK
DBSALT001447
Created by admin on Fri Dec 15 15:09:55 UTC 2023 , Edited by admin on Fri Dec 15 15:09:55 UTC 2023
PRIMARY
MERCK INDEX
m10979
Created by admin on Fri Dec 15 15:09:55 UTC 2023 , Edited by admin on Fri Dec 15 15:09:55 UTC 2023
PRIMARY Merck Index
SMS_ID
100000085256
Created by admin on Fri Dec 15 15:09:55 UTC 2023 , Edited by admin on Fri Dec 15 15:09:55 UTC 2023
PRIMARY
PUBCHEM
3005572
Created by admin on Fri Dec 15 15:09:55 UTC 2023 , Edited by admin on Fri Dec 15 15:09:55 UTC 2023
PRIMARY
EVMPD
SUB04923MIG
Created by admin on Fri Dec 15 15:09:55 UTC 2023 , Edited by admin on Fri Dec 15 15:09:55 UTC 2023
PRIMARY
ChEMBL
CHEMBL1655
Created by admin on Fri Dec 15 15:09:55 UTC 2023 , Edited by admin on Fri Dec 15 15:09:55 UTC 2023
PRIMARY
CAS
89778-27-8
Created by admin on Fri Dec 15 15:09:55 UTC 2023 , Edited by admin on Fri Dec 15 15:09:55 UTC 2023
PRIMARY
Related Record Type Details
Structure of TOREMIFENE
PARENT -> SALT/SOLVATE
Structure of ANHYDROUS CITRIC ACID
PARENT -> SALT/SOLVATE
Related Record Type Details
Structure of TOREMIFENE
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966